|Videos|August 3, 2022
HER2 as a Potential Drug Target and its Prevalence in GI Malignancies
Author(s)Tanios Bekaii-Saab, MD, FACP
An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5